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Abstract
Host genetic factors that modify risk of pneumococcal disease may help target future public health interventions to
individuals at highest risk of disease. We linked data from population-based surveillance for invasive pneumococcal disease
(IPD) with state-based newborn dried bloodspot repositories to identify biological samples from individuals who developed
invasive pneumococcal disease. Genomic DNA was extracted from 366 case and 732 anonymous control samples. TagSNPs
were selected in 34 candidate genes thought to be associated with host response to invasive pneumococcal disease, and a
total of 326 variants were successfully genotyped. Among 543 European Americans (EA) (182 cases and 361 controls), and
166 African Americans (AA) (53 cases and 113 controls), common variants in surfactant protein D (SFTPD) are consistently
underrepresented in IPD. SFTPD variants with the strongest association for IPD are intronic rs17886286 (allelic OR 0.45, 95%
confidence interval (CI) [0.25, 0.82], with p=0.007) in EA and 59 flanking rs12219080 (allelic OR 0.32, 95%CI [0.13, 0.78], with
p=0.009) in AA. Variants in CD46 and IL1R1 are also associated with IPD in both EA and AA, but with effects in different
directions; FAS, IL1B, IL4, IL10, IL12B, SFTPA1, SFTPB, and PTAFR variants are associated (p#0.05) with IPD in EA or AA. We
conclude that variants in SFTPD may protect against IPD in EA and AA and genetic variation in other host response
pathways may also contribute to risk of IPD. While our associations are not corrected for multiple comparisons and
therefore must be replicated in additional cohorts, this pilot study underscores the feasibility of integrating public health
surveillance with existing, prospectively collected, newborn dried blood spot repositories to identify host genetic factors
associated with infectious diseases.
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Introduction
Streptococcus pneumoniae (pneumococcus) is a Gram-positive,
encapsulated bacterium and a leading cause of pneumonia,
meningitis and bloodstream infection in children and the elderly.
An estimated 62,000 cases and 6,000 deaths occur annually from
invasive pneumococcal disease (IPD) in the US.[1] Globally, IPD
causes over a million deaths in children under the age of 5.
Asymptomatic nasopharyngeal colonization with S. pneumoniae is
widespread, but overall few of those colonized develop IPD. In the
U.S., race-dependent infection rates are higher in African
Americans and American Indians than in persons of European
descent.[2]
In 2000 a protein-polysaccharide conjugate vaccine (PCV7) was
licensed in the U.S. targeting seven of the 90 known serotypes of
S. pneumoniae; in 2010 a 13-valent vaccine was also licensed.
Population-based surveillance for IPD through the Active
Bacterial Core surveillance (ABCs) in the US documented an
81% decline in incidence of IPD in children less than two years of
age after introduction of PCV7.[1,3] Nonetheless, cases of IPD
caused by serotypes not covered by the vaccine continue to occur.
Identification of sensitive and specific risk factors for IPD may be
helpful in implementation of public health prevention of IPD.
Risk of IPD has been associated with pathogen virulence, host
susceptibility and epidemiologic factors. Population-based public
health surveillance for IPD has been a critical tool for identifying
epidemiologic risk factors for disease including cigarette smoking,
recent viral respiratory infection, chronic medical conditions,
immunosuppression and lower socioeconomic status.[4] However,
many of these factors are not easily amenable to public health
prevention interventions.
Specific clinical conditions (e.g., HIV-1 infection, and sickle cell
disease) and variants in some host genes [5] are known to modify
risk for IPD. Furthermore, molecular pathways have been
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health surveillance for IPD, such as through ABCs, captures data
for population-based case cohorts, but without prospective
collection of host genetic samples. Most states separately
implement population-based dried bloodspot collection from
newborns (nDBS) for screening for specific inherited traits.
Recently, we reported preliminary results of a pilot study to
integrate ABCs invasive bacterial disease data with a state-based
nDBS repository to identify genetic samples from cases and
controls.[6] Here we use this approach to evaluate candidate host
genetic variants as risk factors for IPD.
Results
tagSNPs associated with IPD
We performed single SNP allelic tests of association stratified by
race/ethnicity in 543 European-Americans (EA), including 182
cases of IPD and 361 controls (Table 1) for 212 SNPs (Tables 2
and S1); and in 166 African-Americans (AA), including 53 cases
and 113 controls for 287 SNPs. Because of the differences in
sample size and its impact on power, we evaluated results based on
both p-value and consistent direction of effect between the two
ancestral groups. Overall, comparing IPD cases to controls, 17
tagSNPs in nine genes (CD46, SFTPA1, SFTPD, IL1B, ILIR1, IL4,
IL10, IL12B, FAS) in EA and 11 tagSNPs in six genes (CD46,
SFTPB, SFTPD, IL1B, ILIR1, and PTAFR) in AA have common
variants that are associated at a liberal threshold of p#0.05
(Tables 3 and S2, and Figure 1). Of these, three candidate genes,
SFTPD, CD46 and IL1R1, have tagSNPs associated with IPD in
both EA and AA; these associations are further described below.
Variants in SFTPD have the strongest and most consistent
associations across EA and AA. SFTPD intronic variants
rs17886286 and rs1998374 are underrepresented among EA
IPD cases compared to controls (allelic OR 0.45 and 0.60, with
p=0.007 and 0.023, respectively). These variants are in moderate
linkage disequilibrium (LD) with each other in EA (SeattleSNPs
r
2=0.732) and thus do not represent independent associations.
Also, these associations do not follow an additive genetic model
given the observation that the genetic effect estimates (odds ratios)
for heterozygotes and homozygotes are similar for each of these
variants, individually (Table S2). Among AA, two different SFTPD
variants (59 flanking rs12219080 and intronic rs17878441) are
underrepresented in IPD cases compared to controls (allelic OR
0.32, and 0.36, with p=0.009 and 0.020, respectively). These
SNPs are not in high LD in AA (SeattleSNPs r
2=0.352). The
association between SFTPD rs17878441 and IPD is specific to AA
given that this SNP is very rare among the EA cohort presented
here (1 heterozygote case and 1 heterozygote control among 508
individuals tested, overall MAF=0.002) and monomorphic in
reference populations such as CEU HapMap and SeattleSNPs EA.
SFTPD rs1998374 and rs12219080 have consistent directions of
effect in EA and AA, although neither is associated in both groups
at p#0.05 (Table 3 and Figure 1).
To explore the joint effects of associated variants in SFTPD,w e
calculated a weighted Genetic Risk Score (GRS) in EA and AA for
significant associations with SFTPD variants (rs1998374 and
rs17886286 in EA, and rs12219080 and rs17878441 in AA).
Together, the two EA SFTPD variants were associated with IPD at
an OR=0.47 (95%CI: 0.26, 0.84) and p-value=0.011. Addition-
ally, the two AA SFTPD variants were associated with IPD at an
Table 1. Study Population Characteristics.
Characteristic Surveillance cohort Genotype cohort Analysis cohort
Cases
(N=366)
Controls
(N=732)
Cases
(N=330)
Controls
(N=637)
Cases
(N=272) Controls (N=546)
Demographics
Median Age in years (range) 1.11 (0-3.2) 1.11 (0-3.2) 1.12 (0-3.2) 1.11 (0-3.2) 1.11 (0-3.2) 1.09 (0-3.2)
Female
1 # (%) 188 (51.4) – 171 (51.8%) – 144 (52.9%) –
Clinical classification # (%)
IPD 366 (100.0%) – 330 (100.0%) – 272 (100.0%) –
Bacteremia only 245 (67.0%) – 223 (67.6%) – 182 (66.9%) –
Pneumonia
2 53 (14.2%) – 43 (13.0%) – 37 (13.6%) –
Meningitis
2 29 (8.2%) – 28 (8.5%) – 23 (8.5%) –
Other
3 39 (10.6%) – 36 (11.0%) 30 (11.0%)
Clinical Outcome – Death 5 (1.3%) 2 (0.6%) 2 (0.7%)
Race
4
European American 265 (72.2%) 534 (72.3%) 240 (72.7%) 452 (71.0%) 182 (66.9%) 361 (66.1%)
African American 62 (16.9%) 124 (16.8%) 53 (16.1%) 113 (17.7%) 53 (19.5%) 113 (20.7%)
American Indian 9 (2.45%) 18 (2.4%) 9 (2.7%) 17 (2.7%) 9 (3.3%) 17 (3.1%)
Asian 19 (5.18%) 38 (5.1%) 16 (4.8%) 31 (4.9%) 16 (5.9%) 31 (5.7%)
Other 12 (3.27%) 24 (3.2%) 12 (3.6%) 24 (3.8%) 12 (4.4%) 24 (4.4%)
1Sex was identified for cases only.
2With or without bacteremia.
3Included in Other: sepsis (7), osteomyelitis or septic arthritis (6), sinusitis (2), otitis (18), cellulitis or abscess (5), UTI (1).
4Race/ethnicity data based on chart abstracted medical records for cases and matched to newborn blood spot repository data for controls.
The Surveillance Cohort was based on all cases of IPD where an nDBS was identified. The Genotype Cohort was defined by samples with amplified genomic DNAo f
adequate quality for genotyping. The Analysis Cohort was defined by removing all outlier EA samples that STRUCTURE identified as having .10% African ancestry.
doi:10.1371/journal.pone.0023413.t001
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viewed cautiously, as the method assumes each SNP to be
independently associated IPD status; however, the SNPs used in
the GRS are in moderate LD (r
2=0.50 in EA, r
2=0.31 in AA).
Variants in CD46 (three in EA and one in AA) are
overrepresented in IPD compared to controls: among EA, intronic
rs1962149, rs2488255, and rs2724385 have allelic ORs between
1.30 to 1.33, and p-values from 0.028 to 0.048 with moderate to
strong LD (HapMap CEU r
2 ranging from 0.684 to 1.00 in pair-
wise comparisons). Intronic CD46 rs41317049 is overrepresented
in IPD among AA compared to controls (allelic OR 2.42 with
p=0.042); rs1962149 has a consistent direction of effect in EA and
AA, but with p.0.05 among AA.
Finally, seven variants in IL1R1 (three in EA and four in AA) are
associated with IPD compared to controls at the p#0.05
threshold. Among EA, intronic rs2160227, rs2287047, and
rs3917318 are underrepresented among IPD cases compared to
controls with very similar allelic ORs (0.72 to 0.73) and p-values
(0.038–0.040). Among EA, LD is high for some (SeattleSNPs
r
2=1.00 for rs2160227 and rs3917318, and r
2=0.80 for
rs2287047 and rs2287049), but not all variants (e.g., SeattleSNPs
r
2=0.302 for rs3917318 and rs2287047). The direction of effect
for IL1R1 variants associated in AA is not consistent: OR point
estimates range from 0.57 to 8.75 with p-values of 0.020 to 0.042
(Table 3). Between EA and AA, the minor alleles for IL1R1
intronic SNPs rs3917318 and rs2160227 and 59 flanking rs949963
are consistently underrepresented among cases compared with
control regardless of race/ethnicity.
Among genes with variants associated with IPD in EA but not AA,
rs1800894 near IL10 is most overrepresented in IPD with an allelic
OR 2.89 and p=0.004. Although not significant, the direction of effect
is the same in AA for this IL10 SNP (OR 1.67, 95% CI [0.35, 7.35]).
IL12B intronic variants rs919766 and rs2195940 are overrepresented
in EA for IPD (allelic OR 1.85, p=0.008 and 1.68, p=0.05,
respectively); among EA, these variants are in complete LD
(SeattleSNPs r
2=1.00). Variant rs2195940 maintains the same
direction of effect with a similar magnitude in AA, though this
association does not reach statistical significance. Furthermore, in a
genotypic test of association, this variant is associated with a large odds
ratio among homozygotes compared to heterozygotes (Table S2).
Finally, SFTPA1 has two variants (intergenic rs4253457 and intronic
rs1914663) with similar allelic OR in EA (0.52 and 0.53, respectively).
Both are in complete LD in EA (SeattleSNPs; r
2=1.00) but are in low
LD in AA (SeattleSNPs r
2=0.119). Of these, rs1914663 has a similar
direction of effect among AA.
Among genes with variants associated with IPD in AA but not
EA, rs905907 near PTAFR has the strongest association with an
allelic OR of 2.38 and p=0.005. The direction of effect in EA is
opposite of that observed for AA for this association (OR =0.90;
95% CI: 0.454, 1.86).
Finally, for IL1B, variants rs2853550 and rs3917365 were
overrepresented, but with low LD in EA (r
2=0.352), while
variants rs1143642 and rs2853550 were underrepresented and
with low LD in AA (r
2=0.141) but moderate LD in EA
(r
2=0.650). rs2853550 was the only tagSNP in our analysis that
was associated (p#0.05) in both AA and EA; but this SNP had
opposite effects in each racial group.
tagSNPs associated with specific clinical outcomes
As expected, most tests of association conducted within specific
clinical outcomes give similar results as tests of association
performed in the larger IPD study. However, we did observe
potentially important differences. Specifically for pneumococcal
bacteremia 15 tagSNPs in eight genes (CD46, SFTPA1, SFTPD,
ILIR1, IL4, IL12B, IL18, and MYD88) and seven tagSNPs in seven
genes (MBL2, SFTPD, IL1B, ILIR1, IL4, and PTAFR) are
associated with cases of pneumococal bacteremia compared to
controls in EA and AA, respectively (Table S3). Thus, in addition
to the genes identified as having variants in EA associated with
IPD, the MYD88 variant rs7744 in the 39 untranslated region is
overrepresented in bacteremia cases among EA (allelic OR 1.49,
Table 2. Candidate Gene List.
tagSNPs
Candidate Gene (GeneID) # Selected
#
Genotyped References
Innate Immune response and signaling pathway genes
CD46 (4179) 25 23 [6,34,35]
CRP (1401) 5 4 [36-38]
FCGR2A (2212) 6 3 [39,40]
FCGR3A (2214) 9 1 [39,40]
IRAK4 (51135) 16 15 [41]
LY96 [MD-2] (23643) 24 24 [42]
MBL2 (4153) 10 10 [43,44]
MyD88 (4615) 3 2 [45]
SFTPA1 (653509) 5 4 [46]
SFTPB (6439) 9 7 [47]
SFTPD (6441) 23 20 [46]
TLR2 (7097) 11 10 [42,48]
TLR9 (54106) 7 3 [49]
Pro- and anti-inflammatory mediators
IFNG (3458) 7 7 [50]
IL1A (3552) 13 12 [51,52]
IL1B (3553) 19 13 [51]
IL1R1 (3554) 35 33 [53]
IL4 (3565) 18 15 [54]
IL6 (3569) 11 8 [55]
IL8 (3576) 3 3 [56,57]
IL10 (3586) 7 7 [58-60]
IL12A (3592) 13 11 [61,62]
IL12B (3593) 9 9 [61,62]
IL18 (3606) 10 10 [63-65]
LTA (4049) 7 7 [66]
TNFa (7124) 5 4 [58,67,68]
Coagulation pathway genes
PROC (5624) 14 5 [69,70]
PTAFR (5724) 8 6 [71]
SERPINE1 [PAI1] (5054) 9 9 [72,73]
Activation/apoptosis and immune regulatory genes
CD40 (958) 11 10 [74]
CD40LG (959) 14 14 [74]
CTLA4 (1493) 4 3 [75]
FAS (355) 7 7 [76]
FASL (356) 7 7 [76,77]
All 34 candidate genes 384 326
Candidate genes were selected based on the published literature and tagSNPs
were selected using existing public variation databases.
doi:10.1371/journal.pone.0023413.t002
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did not reach the p#0.05 threshold. Also, the MBL2 variant
rs930507 is overrepresented in bacteremia cases among AA (allelic
OR 1.82, p=0.046) with a similar effect in EA (allelic OR 1.19)
but with p.0.3.
Additional tagSNPs, particularly in SFTPD, are associated with
pneumonia and meningitis syndromes in EA (Table S4). However,
the sample sizes associated with these outcomes are small (n=17
cases of meningitis, and n=25 cases of pneumonia) precluding
meaningful interpretation of these associations. The AA sample
size associated with these outcomes is also too small (n=2 cases
and n=6 cases, respectively) to permit further analysis.
Discussion
In our evaluation of a population-based cohort for host genetic
variation associated with IPD in children, we identified 27
tagSNPs in 11 genes (CD46, SFTPA1, SFTPB, SFTPD, IL1B,
IL1R1, IL4, IL10, IL12B, FAS and PTAFR) associated in EA or AA
at a liberal significance threshold of p#0.05. In particular, in EA
and AA, variants in the surfactant protein D (SP-D) encoded by
SFTPD (gene ID 6441) are consistently underrepresented in IPD
and pneumococcal bacteremia cases compared to controls,
suggesting that variants in this gene or those in linkage
disequilibrium may confer protection from IPD. This is the first
study linking SFTPD gene variation specifically with clinical IPD.
SP-D is a member of the collectin subgroup in the C-type lectin
superfamily including surfactant protein A (SP-A) and mannose
binding protein. SP-D and SP-A are found primarily in the
respiratory tract and other mucosal surfaces and recent data
suggests that they impact respiratory infections on multiple levels.
Surfactant collectins broadly bind carbohydrates and lipids on the
surface of bacteria and viruses, with specific binding of SP-D to S.
Table 3. Summary of tagSNPs associated with IPD in European-Americans and/or African-Americans.
European-American African-American
Gene tagSNP
Gene
Location
MAF
(Cases)
MAF
(Controls)
Allelic OR
(95% CI) p-value
MAF
(Cases)
MAF
(Controls)
Allelic OR
(95% CI) p-value
Innate Immune response and signaling pathway genes
CD46 rs1962149 Intronic 0.48 0.42 1.30 (1.01, 1.68) 0.045 0.29 0.29 1.54 (0.66, 2.01) 0.667
rs2488255 Intronic 0.49 0.42 1.33 (1.03, 1.72) 0.028 0.36 0.40 0.88 (0.52, 1.37) 0.492
rs2724385 Intronic 0.53 0.47 1.30 (1.00, 1.68) 0.048 0.33 0.32 1.0 (0.64, 1.77) 0.813
rs41317049 Intronic 0.10 0.14 0.70 (0.47, 1.04) 0.079 0.11 0.05 2.42 (1.01, 5.75) 0.042
SFTPA1 rs4253457 Intergenic 0.05 0.09 0.52 (0.30, 0.89) 0.016 0.15 0.10 1.63 (0.82, 3.26) 0.161
rs1914663 Intronic 0.05 0.09 0.53 (0.31, 0.93) 0.024 0.14 0.14 0.98 (0.49, 1.93) 0.944
SFTPB rs3024798 Intronic 0.40 0.36 1.22 (0.94, 1.59) 0.132 0.24 0.15 1.79 (1.00, 3.21) 0.047
SFTPD rs1998374 Intronic 0.08 0.13 0.60 (0.39, 0.94) 0.023 0.22 0.28 0.70 (0.40, 1.22) 0.206
rs12219080 Intronic 0.02 0.04 0.60 (0.27, 1.34) 0.210 0.06 0.16 0.32 (0.13, 0.78) 0.009
rs17878441 Intronic 0.005 0.003 – – 0.06 0.15 0.36 (0.14, 0.88) 0.020
rs17886286 Intronic 0.04 0.08 0.45 (0.25, 0.82) 0.007 0.08 0.06 1.60 (0.65, 3.91) 0.306
Pro- and anti-inflammatory mediators
IL1B rs1143642 Intronic 0.07 0.05 1.56 (0.92, 2.65) 0.095 0.13 0.22 0.51 (0.26, 0.98) 0.042
rs2853550 3’ flanking 0.09 0.06 1.63 (1.01, 2.65) 0.045 0.23 0.33 0.59 (0.35, 1.00) 0.050
rs3917365 3’ flanking 0.09 0.05 1.71 (1.05, 2.81) 0.031 0.12 0.20 1.5 (0.93, 2.65) 0.098
ILIR1 rs949963 Intronic 0.13 0.16 0.8 (0.56, 1.15) 0.227 0.25 0.38 0.57 (0.34, 0.96) 0.034
rs997049 Intronic 0.42 0.41 1.03 (0.79, 1.33) 0.848 0.24 0.14 2.02 (1.11, 3.67) 0.020
rs2160227 Intronic 0.23 0.28 0.74 (0.55, 0.99) 0.040 0.46 0.51 0.83 (0.52, 1.32) 0.826
rs2287047 Intronic 0.20 0.26 0.72 (0.53, 0.98) 0.038 0.57 0.46 1.51 (0.95, 2.42) 0.082
rs2287049 Intronic 0.20 0.26 0.74 (0.54, 1.00) 0.052 0.48 0.36 1.65 (1.02, 2.67) 0.042
rs3917318 3’ untranslated 0.23 0.29 0.73 (0.54, 0.98) 0.038 0.31 0.38 0.74 (0.45, 1.21) 0.228
rs3917272 Intronic 0 0 – – 0.04 0 8.75 (0.97, 79.22) 0.021
IL4 rs2243302 5’ flanking 0.13 0.08 1.61 (1.06, 2.45) 0.023 0.02 0.03 0.70 (1.39, 3.52) 0.663
IL10 rs1800894 5’ flanking 0.05 0.02 2.89 (1.37, 6.12) 0.004 0.03 0.02 1.67 (0.35, 7.35) 0.530
IL12B rs2195940 Intronic 0.11 0.07 1.68 (1.07, 2.63) 0.022 0.17 0.14 1.26 (0.67, 2.38) 0.470
rs919766 Intronic 0.11 0.06 1.85 (1.17, 2.92) 0.008 0.17 0.20 0.82 (0.44, 1.52) 0.527
Coagulation pathway genes
PTAFR rs905907 Intergenic 0.03 0.03 0.90 (0.454, 1.86) 0.772 0.24 0.11 2.38 (1.29, 4.39) 0.005
Activation/apoptosis and immune regulatory genes
FAS rs2234978 Synonymous 0.20 0.26 0.73 (0.54, 0.99) 0.045 0.37 0.29 1.44 (0.88, 1.35) 0.141
Minor allele frequency (MAF), odds ratios (OR), 95% confidence intervals (CI), and p-values for SNPs associated with IPD at p#0.05 in either European-Americans (n=182
cases, 361 controls) or African-Americans (n=53 cases, 113 controls) with allelic (2x2) association test. Associations with unadjusted p#0.05 are in bold.
doi:10.1371/journal.pone.0023413.t003
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2/2 knockout) mice
are associated with persistent pneumococcal colonization, de-
creased clearance of bacterial pathogens, and early onset and
increased levels of S. pneumoniae bacteremia in colonized mice.[7]
Overall, collectins exhibit both pro- and anti-inflammatory
effects[8]: SP-D stimulates phagocytosis and scavenging of
apoptotic cells with pro-inflammatory consequences.[9] Yet, SP-
D and SP-A bind SIRPa [10], TLR2, and TLR4,[11] and
CD14[12] through their globular carbohydrate recognition
domain (CRD) to down-regulate inflammatory cytokines; [11,13]
and sftpd2/2 knockout mice exhibit high levels of pulmonary
inflammation.[14] These findings have led to speculation that
collectins have dual roles: if the collectin collaginase tail is bound
in the absence of a pathogen stimulus, an anti-inflammatory
response results possibly mitigating damage from incidental
environmental stimuli.[15] However, when pathogen signals are
present, pulmonary collectins may provide pro-inflammatory
stimuli for pathogen phagocytosis and NF-kB-mediated cytokine
release.[10] Further study is needed to confirm our tagSNP
associations and further dissect how protection from IPD by
SFTPD variants reflects regulatory functions of SP-D.
Our analysis also identified variants in other innate immune and
coagulation pathway genes (e.g., CRP and PTFAR) and inflam-
matory mediators (e.g., IL1R1, IL1B, IL12B and IL10) that may be
associated with IPD. Since, as an exploratory study, we did not
correct for multiple comparisons, definitive interpretation of these
Figure 1. Summary of tagSNP associations for European-Americans and African Americans. Genomic and association characteristics for
tagSNPs with p#0.05 for IPD among either EA or AA are shown. Threshold lines for p=0.05 (-log10 (0.05) =1.3) and OR=1 are indicated in the
relevant forest plots.
doi:10.1371/journal.pone.0023413.g001
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Nevertheless, our findings support multiple pathways being
involved in host response to IPD. Recent studies also suggest that
additional genes in the toll-like receptor-signaling pathway (e.g.,
NFKB, IKB and MAL) may influence response to IPD. [16–18]
Furthermore, the collectin MBL2 had variants overrepresented in
pneumococcal bacteremia and meningitis, but not for overall IPD.
This suggests the possibility of syndrome-specific host genetic
associations, but our study was underpowered to definitively
evaluate this.
For this analysis, we took an indirect association approach by
selecting and genotyping SNPs that are either causative SNPs or in
LD with the causative SNP. The latter situation most likely applies
to the majority of SNPs found associated with IPD in this study, as
18 of the 27 (67%) associated SNPs are located in introns.
Furthermore, of the four SFTPD variants associated with IPD in
either EA and/or AA (including rs17886286 and rs1998374), all
are intronic. Notably, in SeattleSNPs EA, rs17886286 and
rs1998374 are in complete (r
2=1.00) or high (r
2=0.732) LD
with rs3088308, a coding non-synonymous SNP, while in
SeattleSNPs AA, these SNPs have little to no LD with
rs3088308 (r
2=0.002 for rs17886286 and r
2=0.028 for
rs1998374) and are not associated with IPD in AA. The two
SFTPD variants that are associated with IPD in AA are in
moderate LD with a different coding non-synonymous SNP,
rs4469829, which is monomorphic in EA (r
2=0.613 for
rs17878441 and r
2=0.620 for rs12219080). Furthermore, SFTPD
variant rs721917, a non-synonymous SNP known to reduce serum
levels of SP-D in EA, is in LD with rs1998374 in AA (SeattleSNPs
r
2=0.645) but not EA (SeattleSNPs r
2=0.096). Thus, differences
in LD patterns between ancestral populations may help to explain
the disparate signals observed in EA compared to AA.
Our primary goal was to assess the feasibility of cross-linking
surveillance data with an nDBS repository to perform tagSNP
genomic studies, and toward this end we were highly successful:
82% of surveillance cases were linked to an nDBS, and 88% of
samples successfully genotyped. Several key issues associated with
this experience deserve emphasis. First, the completeness of IPD
case surveillance in ABCs through use of active surveillance
methods and routine audits of laboratory records combined with
the overall low incidence of IPD in the general population support
our assumption that controls were at low risk of having had IPD
outside the surveillance time-period. Second, efficient linking of
surveillance cases to nDBS samples was critical to minimize bias,
but this linkage depends on consent requirements for nDBS use,
which differ by state and continue to evolve.[19] Third, nearly a
quarter of individuals identified as European-American through
surveillance were found to have genetic characteristics indicating
.10% African ancestry. Given differences in allele frequencies
and LD between EA and AA populations, misclassification of
ancestry can result in confounding. Although self-reported
ancestry can be accurate in some settings,[20] our study
underscores that more complete genetic evaluation for ancestry
may be important to control for population stratification in some
settings. Finally, the tagSNP approach we used is based on the
assumption that most disease-causing variation will be captured
through LD with common tagSNPs. Recent concern [21,22] that
low frequency host variation contributes substantial disease
causation may underscore the need for large-scale gene sequenc-
ing and not a tagSNP analysis. Our earlier findings demonstrating
that gene sequencing can be performed with high-fidelity using
DNA from these nDBS samples [6] suggests that application of
large-scale sequencing for initial variation discovery could be
useful in future replication studies.
Our findings are not corrected for multiple comparisons and
therefore should be viewed as preliminary with definitive proof
requiring replication in additional cohorts. However, given our
study results and the wealth of existing public health surveillance
data and existing large repositories of nDBS, replication studies
powered to detect associations with IPD and invasive disease
caused by other vaccine preventable encapsulated bacteria (e.g., N.
meningitidis and H. influenzae) should be feasible and could help
further define host genetic risk factors for IPD and other infectious
diseases and permit economic and attributable risk analyses to
determine the usefulness of such risk factors for implementation of
public health prevention interventions.
Materials and Methods
Ethics Statement
The protocol for this study was reviewed and approved by the
institutional review boards at the Minnesota State Department of
Health and the Centers for Disease Control and Prevention
(CDC). Written informed consent was solicited from individuals
providing nDBS or their guardians. The ethics approvals allowed
for use of anonymous samples in cases where the individuals or
their guardians provided written informed consent or where they
could not be contacted; nDBS samples from individuals who
declined consent were removed from this analysis. After
determination of consent status, the database was made anony-
mous by delinking from surveillance identifiers, at which point
CDC closed the project, allowing anonymous genotyping to
proceed using the coded nDBS and study database. The
University of Washington subsequently provided a certificate of
exemption for this study.
Subject Ascertainment
As previously described [6], IPD cases in the state of Minnesota
were identified through Active Bacterial Core surveillance (ABCs),
coordinated through the Centers for Disease Control and
Prevention’s Emerging Infections Program. Cases of IPD were
defined as individuals born between January 1, 1997 and
December 31, 2000 who had isolation of S. pneumoniae from a
normally sterile site during the same time period. nDBS collected
from cases during the course of normal newborn screening were
identified by cross-linking ABCs identifiers with the Minnesota
newborn screening program. For each case nDBS identified, two
anonymous control nDBS were selected based on surveillance and
newborn screening data by matching case and control race/
ethnicity, date of birth, and, when possible, hospital of birth.
Parents or guardians of cases were contacted by mail for written
consent. Surveillance data and nDBS were included for all cases
with parental consent and those who did not respond after two
mailings. ABCs data and case and control nDBS were stripped of
linkage to personal identifiers.
Study cohort
Overall, 445 individuals were identified as meeting the IPD case
definition. Of these cases, stored nDBS were identified for 366
(82%) with a median age of 1.1 years (range 0–3.2 years) and
nearly equal numbers of males and females (Table 1). Anonymous
nDBS were matched to cases by date of birth and identified race
for 732 controls (82% of controls were also matched to cases by
hospital of birth). Among these 1098 cases and controls
(Surveillance Cohort), amplified DNA of adequate quality for
genotyping was obtained from 967 (88%) representing 330 cases
and 637 controls (Genotyped Cohort). Population substructure
analysis indicated that 149 individuals (58 cases and 91 controls) in
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data as having European American (EA) ancestry had genotypes
consistent with $10% African ancestry. These cases were omitted
from the final Analysis Cohort leaving 543 EA (182 cases and 361
controls), 166 AA (53 cases and 113 controls), and 109 from other
ancestral backgrounds (Table 1). The 709 individuals (235 cases
and 474 controls) of EA and AA race/ethnicity are referred to as
the Analysis Cohort.
Candidate Gene and tagSNP Selection
We selected 34 candidate genes (Tables 2 and S1) based on
publications prior to 2007 reporting an association of the gene or
protein product with IPD, pneumonia or sepsis, or laboratory
evidence for a role in host response to S. pneumoniae or other
encapsulated bacteria (e.g., N. meningitidis). TagSNPs were selected for
African-Americans and European-Americans using software LDSe-
lect [23] (r
2.0.64; minor allele frequency .5%) and data from
SeattleSNPs [24], the Environmental Genome Project [25], Perlegen
[26], and the International HapMap Project [27]. Amplified DNA
samples were genotyped for 384 tagSNPs with a custom Illumina
GoldenGate assay [28] by the Center for Inherited Disease Research
(CIDR) as part of the National Heart Lung and Blood Institute
(NHLBI) Re-sequencing and Genotyping (RSnG) service.
DNA Extraction and SNP Genotyping
De-identified genomic DNA extracted from 1,022 dried blood
spots was whole genome amplified using a multiple displacement
method (Molecular Staging, Inc. (MSI), New Haven, CT
USA)[29] from a single 3-mm punch from K inch dried blood
spots.
A total of 326 (85%) of 384 selected tagSNPs were successfully
genotyped (Tables 2 and S1). Of 326 successfully genotyped,
tagSNPs fell into 5 broad biological categories: 13 innate immune
response genes with 126 SNPs (39%), 13 pro- and anti-
inflammatory mediators with 139 SNPs (43%), three genes in
coagulation pathways genes with 20 SNPs (6%), and five genes in
activation/apoptosis pathways with 41 SNPs (12%) (Tables 2 and
S1). Genes with 50% or more SNPs targeted but not successfully
genotyped included: FCGR3A (8 of 9 SNPs failed genotyping),
PROC (9 of 14 SNPs), TLR9 (4 of 7 SNPs) and FCGR2A (3 of 6
SNPs). For the IPD analysis, a total of 212 (65%) and 287(88%)
genotyped SNPs had .95% genotyping efficiency, had a minor
allele frequency (MAF) .0.01, and met Hardy-Weinberg
Equilibrium (HWE) criteria of p.0.0001 among EA and AA,
respectively. The majority of SNPs genotyped for CD40LG (10 of
14) were out of HWE (pEAcontrols,0.0001) and subsequently
omitted from further analyses. Genotyping associated with the
bacteremia case definition included: 120 cases and 361 controls
were included for EA with 213 SNPs passing QC, and 39 cases
and 113 controls among AA with 281 SNPs passing QC. We also
report genotyping data from EA for the 25 cases of pneumonia
and 17 cases of meningitis compared to 361 controls, with 211
SNPs passing QC for each of those analyses.
Study Population Demographics and Ancestry
Population stratification was evaluated using STRUCTURE
(version 2.2, http://pritch.bsd.uchicago.edu/structure.html) prior
to performing SNP quality control or testing for associa-
tion.[30,31] Discrepancies were noted between genotype inferred
ancestry and surveillance database assigned ancestry using 274
SNPs with a minor allele frequency .1%. Samples labeled as
European-American that were inferred to have .10% African-
American ancestry were omitted from further analysis.
Statistical Analysis
Only SNPs that passed quality control measures (minor allele
frequency .1%, Hardy-Weinberg Equilibrium (HWE) p.0.0001
in controls, and genotyping efficiency .95%) were considered for
analysis. All analyses were stratified by race/ethnicity, and tests of
association were performed using PLINK [32] or STATA (version
10). Due to the small number of non-European, non-African
samples, we did not analyze data from those samples. Exclusion of
individual case or control samples due to genotyping quality
control criteria and genetic ancestry disrupted the original case-
control matching. In order to maximize the sample size for this
exploratory analysis, tagSNP associations were assessed through
an unmatched comparison of IPD cases to controls. Two-tailed x
2
tests were used with p#0.05 considered significant without
correction for multiple comparisons. Both allelic and genotypic
tests of associations were performed for all SNPs. LD estimates
were obtained through SeattleSNPs Genome Variation Server at
http://gvs.gs.washington.edu/GVS/using data from the Interna-
tional HapMap Project [27] and SeattleSNPs [24] as indicated.
A weighted Genetic Risk Score (GRS) was calculated for SFTPD
by PLINK for every participant, stratified by race/ethnicity, using
SNPs that were associated with IPD status at p,0.05. The GRS is
simply a sum across SNPs of the number of risk alleles (0, 1, or 2)
at that SNP, multiplied by the odds ratio of the association.
Participants with incomplete genotype data at any SNP used in the
GRS were excluded from analysis. Logistic regression, with
continuous GRS as the independent variable, was used to evaluate
the joint effects of associated genetic variants with IPD status.
The primary analysis was based on ABCs data for IPD case
status. We also evaluated other clinical outcomes of pneumococcal
bacteremia, pneumonia, or meningitis, defined by S. pneumoniae
cultured from blood only with no other site-specific diagnosis,
isolation from pleural fluid or a clinician diagnosis of pneumonia,
and isolation from cerebrospinal fluid or a clinician diagnosis of
meningitis, respectively. Because of the small numbers of
pneumonia and meningitis cases, we used Fisher’s exact test for
these analyses. Association results were also plotted graphically
using Synthesis-View.[33]
Supporting Information
Table S1 Candidate SNP List. Characteristicsof tagging SNPs
(based on linkage disequilibrium; r2) are listed for each selected gene
and the genotyping outcome. The minor allele frequency (MAF) in
thefullgenotypedcohortisalsoprovided.SNPswithanasterisk(*)do
not have rsIDs available. Flanking sequences used to design primers
for these are listed below with the SNP indicated in brackets:
TLR2_004667_rsNA: AGGTCCTGGATGCCCGAAGCTTCA-
AGAAAATACTGGTTGGGCACTTAGCTTTCCCTGTGGT-
TGCCAATCCCACGCAGGCC.GCCTCTAGCGTCTCGATT-
CG[C/T]TTTTCTCTGACCTGGAACCTCCGCCAAGCCCC-
CAGCTCTCTTCTTCGACCCAGCCTTGCACSGGGCAGC-
TGTCGGGGCAGGACCCGCCTCTGGCCTGTCG. TLR2_0
19165_rsNA: AATATTCATCTGAATCAAATTATCTATGAT-
AACCTATTTAAATGAACAGCATCATGCACCTGAATTGG-
AGAAACAAAACTGAT. ATTTMAAATGATATAAA[C/T]T-
TAGTGTTAAATGTGGCCTCATGGATCAGACAGCTATC-
TGGTCCTTTCTGAGTCCATATAGCTGCCATTATTAAAA-
GTTCTGCACTCTATGACTCATCAC. TLR2_019827_rsNA:
CAAAAGGAGAGATAATTAGACAGTTTGTAGACGAATTC-
ATAACCCTAATTCTCTAATTGTTGGTAGCCTCCATTGA-
TGATAAT. TAATAGTGGAGCCTTAG[A/G]TAAATACTA-
CTATTGCTTCCCCGTTGATGAMCCCTGTAGCACACAG-
TGTCCCACAGGGAACTGTCTCTTGTGCCCCTCTAGCA-
Host Genetics of Invasive Pneumococcal Disease
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23413TATATTTTTATCTATGA.TLR2_023003_rsNA: ACTTAAAC-
ACTGCTTTTTGCATTTACTTCTAGGCAGGAAGACAGG-
GTTCTGATGGTGTGAGTCTCCTTCAACTCAGCAAACC.
ACCTTGGTCTGCCTCGAG[C/T]TTCCAACACCCCTCCT-
GCCTGCTAGTGATAGGTGTGAGGCAGGTTGATGAACA-
TGGAACTTTTTTCTTTTGGTCCCAAAGCATGCTACTC-
CTGGAGTTTC.
(DOC)
Table S2 tagSNPs in candidate genes found associated
with IPD. For European-Americans (182 Cases and 361
Controls), and African-Americans (53 Cases and 113 Controls).
Allelic (262) and genotypic (263) models are used to calculate
allelic, heterozygote and homozygote OR, 95% confidence
intervals (CI) and minor allele frequency (MAF). Variants are
ordered by decreasing significance of the allelic p-value.
(DOC)
Table S3 tagSNPs in candidate genes found associated
with bacteremia. For European-Americans (120 Cases and 361
Controls) with 213 SNPs passing QC (HWE .0.0001, MAF
.0.01, Genotyping efficiency .90%) and African-Americans (39
Cases and 113 Controls) with 281 SNPs passing QC. Allelic (262)
and genotypic (263) models are used to calculate allelic,
heterozygote and homozygote OR, 95% confidence intervals
(CI) and minor allele frequency (MAF). Variants are ordered by
decreasing significance of the allelic p-value.
(DOC)
Table S4 tagSNPs in candidate genes associated with
pneumonia and meningitis for European-Americans
(EA). 25 Cases and 361 Controls with 211 SNPs passing QC
(HWE .0.0001, MAF .0.01, Genotyping efficiency .90%).
Allelic (262) and genotypic (263) models are used to calculate
allelic, heterozygote and homozygote OR, 95% confidence
intervals (CI) and minor allele frequency (MAF). Variants are
ordered by decreasing significance of the allelic p-value.
(DOC)
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